Preliminary activity of capmatinib with gefitinib in NSCLC. [electronic resource]
Producer: 20190617Description: e517 p. digitalISSN:- 1474-5488
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzamides
- Biomarkers, Tumor -- antagonists & inhibitors
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- ErbB Receptors -- antagonists & inhibitors
- Gefitinib -- administration & dosage
- Genetic Predisposition to Disease
- Humans
- Imidazoles -- administration & dosage
- Lung Neoplasms -- drug therapy
- Maximum Tolerated Dose
- Mutation
- Phenotype
- Protein Kinase Inhibitors -- administration & dosage
- Time Factors
- Treatment Outcome
- Triazines -- administration & dosage
No physical items for this record
Publication Type: News
There are no comments on this title.
Log in to your account to post a comment.